Brought to you by 
Cubist buys Adolor for $198mm in cash plus potential earn-outs
13 Dec 2011
Executive Summary
Cubist Pharmaceuticals Inc. (therapies for the acute care market) has agreed to acquire all the outstanding shares of fellow public company Adolor Corp. (pain and gastrointestinal disorders) for about $198mm in cash. (Cubist is paying $4.25 per share, a 131% premium.)
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cubist buys Adolor for $198mm in cash plus potential earn-outs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice